Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guidance and tools
Guidance and tools
Choosing investments Choosing accounts ISA calculator Retirement calculators
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
AstraZeneca experimental lung cancer drug shows promising results
(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday. AstraZeneca said high-level overall survival rates from the global Tropion-Lung01 trial "numerically favoured" datopotamab deruxtecan compared to standard chemotherapy drug docetaxel in the overall trial population of patients with non-small cell lung cancer (NSCLC) treated with at least one prior therapy.
NSCLC is to the most common form of lung cancer.
In the pre-specified subgroup of patients with non-squamous NSCLC, datopotamab deruxtecan also showed a "clinically meaningful" improvement in overall survival compared to docetaxel.
Survival rates did not reach statistical significance in the overall trial population, however.
Susan Galbraith, executive vice president for oncology research and development at AstraZeneca, said: "These results reinforce the potential for datopotamab deruxtecan to replaced conventional chemotherapy in this late-line setting and underscore our confidence in ongoing trials, evaluating this therapy in first line lung cancer."
Ken Takeshita, global head of R&D at Japan's Daiichi Sankyo, which is developing the drug with AstraZeneca, said: "These data will support our ongoing discussions with regulatory authorities globally to potentially bring datopotamab deruxtecan to patients as quickly as possible, and mark another step forward in creating new standards of care for patients with cancer."
AstraZeneca noted that the safety profile of datopotamab deruxtecan was "consistent" with previous analysis, including fewer dose reductions or discontinuations due to adverse events when compared to docetaxel.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Doing Business with Fidelity | Diversity, Equity & Inclusion Reports | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing policy
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.